How Unified Platform Approaches Deliver Up To 13x ROI

More than a decade ago, sponsors began deploying virtual and remote solutions to support clinical trial execution. The COVID-19 pandemic, however, catalyzed rapid and extensive adoption of these solutions to reduce the risk of transmitting infection, minimize delays and disruptions, accelerate the collection of clinical research data, facilitate participant access to clinical studies, and lower participation burden.

Commonly referred to as decentralized clinical trials (DCTs), sponsors and contract research organizations (CROs) are now looking for insights into optimizing the value of DCT deployments. This Tufts CSDD Impact Report presents the results of an initial Tufts CSDD study quantifying the net financial return on DCT investment. Value was measured by changes in expected net present value (eNPV). The study looked at three factors for which data were available that can impact eNPV.